spectively). An association between VEGF and bFGF was also found (R = 0.59, p < 0.0005). Serum level of TGFβ β β β β1 revealed no relationship with any marker of acute-phase activation, remaining growth factors, or dialysis adequacy. Positive correlation between TGFβ β β β β1 concentration and dialysate-to-plasma ratio for creatinine in PET (R = 0.35, p < 0.05) was found. In addition, patients with lower solute transport (low/low-average transporters) had lower serum levels of both bFGF and TGFβ β β β β1 compared to patients with higher solute transport. Patients with total wCCr > 60 L/ week/m 2 were characterized by lower levels of bFGF and IL-6. Serum level of IL-6 and plasma levels of bFGF and VEGF were significantly lower among subjects with residual renal function (RRF) > 2.0 mL/minute. ♦ ♦ ♦ ♦ ♦ Conclusions. Our results indicate that systemic inflammation in peritoneal dialysis patients is associated with increased plasma VEGF and bFGF but not TGFβ β β β β1. The negative correlation with RRF suggests that either the renal clearance of these cytokines and growth factors may contribute to their elimination, or cytokines and growth factors have a negative impact on RRF. We also suggest an association between serum levels of growth factors tested and peritoneal membrane function.
A ccording to current concepts, chronic renal failure may be considered a chronic inflammatory state (1) , as evidenced by elevated serum levels of selected cytokines and/or acute-phase reactants. Chronic inflammation may, in turn, lead to serious complications of uremia, such as malnutrition or progression of atherosclerosis (2) (3) (4) (5) (6) (7) (8) . Growth factors are also involved in many pathological processes in the course of chronic renal failure, such as atherogenesis, vessel wall remodeling, and, particularly, stimulation of interstitial kidney fibrosis with subsequent loss of renal function and progression of renal insufficiency (9) (10) (11) (12) (13) (14) (15) (16) (17) .
It has been suggested recently that local intraperitoneal release of growth factors [transforming growth factor β1 (TGFβ1) and vascular endothelial growth factor (VEGF)] may also be responsible for the progressive increase in the peritoneal permeability-area product (transport) for small solutes in long-term peritoneal dialysis (PD) patients (18) (19) (20) . In the available literature there is no report linking peritoneal membrane permeability and basic fibroblast growth factor (bFGF). In addition, the relationship between plasma levels of growth factors and peritoneal membrane transport, as well as dialysis adequacy, remains largely unknown. We hypothesize that there may be an association between circulating cytokines, growth factors, and acute-phase reactants in PD patients and that plasma levels of growth factors may impact on peritoneal membrane permeability and residual renal function (RRF).
The aim of this preliminary, single-center, cross-sectional study was to evaluate the possible relationship between plasma levels of certain growth factors (bFGF, VEGF, TGFβ1) and the indices of inflammatory process activation [serum interleukin (IL)-6, C-reactive protein (CRP), and fibrinogen] in patients treated with continuous ambulatory peritoneal dialysis (CAPD). The potential link between the above substances and peritoneal transport characteristics, as well as dialysis adequacy and RRF was also studied.
M E T H O D S

STUDY POPULATION
Thirty-two CAPD subjects selected from a total of 55 patients treated in our unit (19 women, 13 men; age 23 -80 years, mean 53.6 ± 13.7 years; median period of dialysis 19.5 months, range 2 -79 months) were included into the study. Only patients that remained peritonitis free for a minimum 3-month period and were hepatitis B surface antigen-negative and anti-hepatitis C virus antibody-negative were enrolled. No clinical signs or symptoms of other inflammatory disease of infectious or noninfectious origin were observed 3 months prior to and during the study. The etiology of end-stage renal disease in the analyzed group was as follows: chronic glomerulopathy in 10 subjects, amyloidosis and polycystic kidney disease in 2 each, chronic pyelonephritis, lithium nephropathy, and hypertensive nephropathy in 1 each. Due to late referral to the dialysis unit, it was impossible to establish the etiology of underlying renal disease that led to uremia in 15 patients. Patients were dialyzed using either Baxter Twin Bag (Baxter Healthcare SA, Castlebar, Ireland) or Fresenius ANDY Plus (Fresenius Medical Care GmbH, Bad Homburg, Germany) systems with glucose-based solutions. The glucose concentration in daily dialysate instilled into the peritoneal cavity ranged from 1.36% to 3.06% (median 1.59%).
LABORATORY ANALYSES
Fasting blood samples taken for analyses of growth factors and acute-phase markers were centrifuged at 4°C at 1000g for 15 -30 minutes and frozen at -70°C.
Blood samples for TGFβ1 were taken using EDTA tubes. As TGFβ1 is secreted from cells as a latent complex, the samples were pretreated with 2.5 mol/L acetic acid to activate the immunoreactive form of this growth factor and then neutralized with 2.7 mol/L NaOH/1 mol/L HEPES mixture prior to the assay. An ELISA method was used for the measurement of plasma TGFβ1 concentration (Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, England). Basic FGF level was measured in citrated plasma using ELISA technique with the commercially available diagnostic kit designed for detection of very low concentrations of this factor (Quantikine High Sensitivity; R&D Systems, Minneapolis, Minnesota, USA). VEGF was measured in citrated plasma and IL-6 in serum using ELISA kits (Quantikine, R&D Systems). Serum concentration of CRP was assayed with the immunonephelometric method, and fibrinogen using Multifibren U reagent (Dade Behring Marburg GmbH, Marburg, Germany). All analyses were performed in duplicate. Intra-assay variability for growth factors and IL-6 measurements was below 6%.
DIALYSIS ADEQUACY AND ASSESSMENT OF MEMBRANE PERMEABILITY
Both dialysis and residual components of Kt/V and normalized weekly creatinine clearance (wCCr) were calculated based on 24-hour urine and dialysate collections performed prior to the scheduled visit to the PD unit. Serum, urine, and dialysate urea and creatinine levels were analyzed using Hitachi 917 equipment (Roche Diagnostics, Division of Hoffmann-La Roche, Basel, Switzerland). Calculations of Kt/V and wCCr were performed using original Polish software, Nephron 97 for Windows (DDPS, Kraków, Poland). Distribution volume in the mentioned software is calculated according to Watson formulas (21) . Residual renal function is expressed as the mean value of the sum of residual renal urea and creatinine clearances.
The peritoneal equilibration test (PET) was performed according to the method described by Twardowski (22, 23) .
The above protocol was reviewed and approved by the local ethics committee.
STATISTICAL ANALYSIS
Statistical analysis of the data was performed using Statistica 5.1 software (StatSoft, Tulsa, Oklahoma, USA). Shapiro-Wilk's W-test of normality was used for data distribution analysis. All normally distributed variables are presented as mean ± SD and those with nonnormal distribution as median and range. Student's t-test for intergroup comparisons and Pearson test for correlations between variables were used for normally distributed data, whereas MannWhitney U and Spearman R test for those of nonparametric distribution. We considered p values less than 0.05 statistically significant.
R E S U L T S
Mean or median values as well as range or standard deviation of serum levels of markers reflecting inflammatory process activity, and plasma levels of growth factors are summarized in Table 1 . The results of adequacy assessment and dialysate-to-plasma ratio of creatinine (D/Pcreat) are shown in Table 2 .
Statistically significant positive correlation was found between plasma bFGF and IL-6 (R = 0.36, p < 0.05), as well as between bFGF and fibrinogen (R = 0.39, p < 0.05). Correlation between bFGF and serum CRP was borderline significant (R = 0.31, p = 0.08). Plasma VEGF was associated with IL-6 and CRP (R = 0.65, p < 0.0001 and R = 0.51, p < 0.005, respectively), but not with serum fibrinogen [R = 0.21, p = not significant (NS)]. Plasma levels of bFGF and VEGF correlated also with time on PD (R = 0.41, p < 0.05 for both factors). Significant positive correlation was found between plasma VEGF and bFGF (R = 0.59, p < 0.0005). No relationship was observed between serum TGFβ1 and any of the parameters reflecting inflammatory process (IL-6, CRP, and fibrinogen) or the other growth factors.
Significant correlations were also found between RRF and bFGF, VEGF, and acute-phase reactants. These correlations are summarized in Table 3 . Although the association between indices of adequacy and CRP did not reach statistical significance, all showed the same tendency as for VEGF, bFGF, and IL-6.
Serum level of TGFβ1 revealed no relationship with any adequacy parameters. However, we found positive correlation between TGFβ1 and D/Pcreat in the PET (R = 0.35, p < 0.05).
Dividing our patients according to the D/Pcreat value of 0.6 [i.e., low/low-average (L/LA) transporters, n = 22, D/P 0.53 ± 0.07; and high/high-average (H/HA) transporters, n = 10, D/P 0.73 ± 0.06], we found significantly lower bFGF concentration in the first group compared to the second (1.1 pg/mL, range 0.2 -18.9 pg/mL, vs 1.8 pg/mL, range 0.7 -21.5 pg/mL; p < 0.05, Mann-Whitney U test). A similar difference was found for TGFβ1 (7.7 ± 1.6 pg/mL in L/LA vs 9.13 ± 1.2 pg/mL in H/HA transporters; p < 0.05, Student's t-test). Plasma VEGF also tended to be lower in L/LA transporters, but this difference was not significant (median 32.7 vs 39.0 pg/mL, p = NS).
On dividing the study group into two subgroups according to the total value of wCCr = 60 L/week/m 2 , we found that serum levels of bFGF and IL-6 were 3.78 0.81-9.5 1.8-3.5 bFGF = basic fibroblast growth factor; TGFβ1 = transforming growth factor β1; VEGF = vascular endothelial growth factor; CRP = C-reactive protein; IL-6 = interleukin-6. (Table 4 ). Such differences were absent in comparisons of subjects with total Kt/V value above or below 2.0. Patients with RRF greater than 2.0 mL/minute (n = 9) were characterized by significantly lower levels of IL-6 compared to those without RRF (< 2.0 mL/ minute, n = 23): 1.3 pg/mL (1.1 -4.0 pg/mL) vs 2.8 pg/mL (1.1 -20.3 pg/mL), p < 0.005, MannWhitney U test. In addition, patients with better preserved RRF were characterized by significantly lower levels of VEGF and bFGF (Table 5 ).
We also looked for possible relationships between the daily mean glucose concentration of dialysate instilled into the peritoneal cavity and the levels of cytokines and growth factors. We found a positive, statistically significant correlation of the mean concentration of glucose in daily dialysate with plasma VEGF (R = 0.53, p < 0.005), and borderline correlation with bFGF (R = 0.33, p = 0.06). As expected, the mean glucose concentration in daily dialysate was positively correlated with time on dialysis (R = 0.43, p < 0.01) and inversely with RRF (R = -0.55, p < 0.001). In addition, we compared plasma levels of growth factors, cytokines, and acute-phase reactants in patients using PD fluid having the lowest available glucose concentration (1.36% -1.5%, n = 10) with those using higher concentrations (median glucose concentration 1.81%, range 1.59% -3.06%; n = 22). Plasma levels of all analyzed growth factors were higher in patients using dialysis fluid with higher glucose content, although this difference was statistically significant only for VEGF (Table 6 ). No statistical difference was found for IL-6, CRP, or fibrinogen. 
DISCUSSION
Our study revealed statistically significant correlations between chronic inflammatory process, reflected by serum levels of IL-6, CRP, and fibrinogen, and plasma VEGF and bFGF concentrations. This is the first evidence that plasma bFGF and VEGF are associated with systemic inflammation in PD patients. A link between proinflammatory cytokines and VEGF was demonstrated recently for human peritoneal mesothelial cells in vitro. Mandl-Weber et al. found that incubation of mesothelial cells with IL-1α, tumor necrosis factor α (TNFα), and thrombin results in a significant increase in VEGF synthesis (24) .
A negative relationship between dialysis adequacy, as represented by total wCCr, total Kt/V, and serum levels of VEGF, bFGF, and IL-6 was also observed. However, this association with total values of adequacy parameters was caused only by the relationship with residual renal but not peritoneal components of solute clearance. Similar results were obtained by Wang et al., who found a negative correlation between residual clearance and another marker of chronic inflammation, hyaluronan (r = -0.49, p < 0.005). No relationship between RRF and IL-1β or CRP was noted in that study, although RRF tended to correlate with serum level of TNFα (25) . However, Espinoza et al. did find an inverse relationship between plasma TNFα and residual renal clearance (r = -0.37, p < 0.05) (26) . Recently, Chung et al. demonstrated that the initial value of serum CRP predicts the further decline of renal function during 1-year of follow-up (27) . Taken together, these observations suggest that RRF is responsible for better clearance of growth factors and proinflammatory cytokines. Alternatively, these substances may adversely impact on RRF, leading to further decline of renal function. Chronic inflammation is a well-recognized risk factor of interstitial fibrosis and progressive loss of renal function in chronic renal failure (14, 15, 28) . TGFβ1 is considered the key growth factor in the process of interstitial fibrosis and progression of renal failure (15) . We failed to demonstrate the relationship between this growth factor and RRF or peritoneal components of dialysis adequacy, whereas such an association was strong for plasma bFGF and for VEGF especially. Our results do not allow us to state whether this association is caused by impaired renal clearance of growth factors or, conversely, a negative impact of growth factors on residual diuresis; however, both these effects are possible.
Residual renal function correlated inversely with dialysis dose, which in turn may adversely affect biocompatibility of the dialysis procedure as exposure to bioincompatible dialysate increases. Hence, lower serum levels of IL-6, VEGF, and bFGF in patients with well-preserved residual diuresis may reflect lower exposure to bioincompatible treatment. Indeed, in our study, positive correlation was found between plasma concentrations of VEGF and bFGF and volume of dialysate delivered daily to the peritoneal cavity. This could be explained, however, by the inverse relationship between the volume of dialysate delivered daily and RRF, resulting from increased dialysis prescription to maintain dialysis adequacy. As demonstrated in in vitro studies, high glucose dialysate stimulates synthesis of TGFβ1 by human peritoneal mesothelial cells (29); it is not known if it stimulates bFGF synthesis. High glucose medium (4.0%) has also been shown to increase bFGF mRNA in cultured human mesothelial cells by 2.5-fold compared to control medium, and to increase bFGF concentration in culture supernatant. This supernatant was a potent stimulus of peritoneal fibroblast proliferation (30) . As demonstrated recently, human mesothelial cells may release VEGF if they are incubated with glycated albumin but not with glucose itself (24) . Our clinical results seem to confirm such experimental data as we found a relationship between plasma levels of VEGF and bFGF and mean glucose concentration in daily dialysate. These results are at least in part confounded by the fact that utilization of dialysate with higher glucose content increases with time on dialysis. Plasma levels of bFGF and TGFβ1 were significantly higher among patients with higher peritoneal membrane permeability. TGFβ1, but not bFGF or VEGF concentration revealed positive correlation with D/Pcreat. Recently, Margetts et al. described changes in peritoneal membrane permeability after intraperitoneal injection of an adenoviral vector activating the gene for TGFβ1 in an animal model. They observed the development of different morphological and functional changes within the peritoneal membrane, resulting in markedly increased peritoneal membrane solute transport (18) . Park et al. recently presented data suggesting that high glucose concentration may stimulate synthesis of VEGF, a potent stimulator of neoangiogenesis (31). Zweers et al. reported local production of VEGF and TGFβ1 in the peritoneal membrane and a correlation between VEGF and the mass transfer area coefficient of creatinine (19) . Furthermore, increased extracellular matrix production, caused by exposure to hyperosmolar glucose solution, is mediated by TGFβ1 (20) . These observations may explain the mechanism of the increasing peritoneal membrane permeability secondary to prolonged exposure to glucose-containing dialysis fluid (32, 33) , although these changes may be caused not only by glucose itself but also by products of its degradation and advanced glycation. Little information is available on serum levels of growth factors and peritoneal transport characteristics. Our results, however, are in accordance with these experimental data, clearly confirming the relationship between serum TGFβ1 and peritoneal membrane permeability, and suggesting the same is true for bFGF. The biological effects of bFGF, TGFβ1, and VEGF on peritoneal membrane function may be similar since bFGF is also a potent stimulator of neoangiogenesis (34) .
Systemic inflammation could have an impact on peritoneal membrane permeability. As demonstrated recently, an elevated serum CRP may predict early increases in peritoneal membrane permeability (27) . The cited paper does not explain the mechanisms of this association, but these findings are in agreement with our results. We demonstrated correlations between circulating bFGF, VEGF, and IL-6, and CRP and fibrinogen. It is possible that the release of growth factors, triggered by proinflammatory cytokines, accounts for the association between chronic inflammation, increasing peritoneal membrane permeability, and loss of RRF, although our study suggests a common link through bFGF rather than TGFβ1. One of the important findings of this study is the observation that plasma bFGF and VEGF levels behave very similarly, and both differ from TGFβ1. TGFβ1 was normally distributed, whereas both VEGF and bFGF were highly skewed and shifted to the left. VEGF and bFGF revealed very similar correlations with other tested parameters and were correlated with each other.
We realize that the cross-sectional design and relatively small sample size of our study are serious limitations. Therefore, all the conclusions are preliminary and should be drawn with caution. Nevertheless, our findings suggest an association between systemic inflammation and plasma levels of selected growth factors in patients on PD. Such an association may have different potential biological effects on dialysis adequacy (and predominantly on its residual components) and on peritoneal membrane permeability.
